Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
Coll freshman Bad
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
Coll. sophomore Bad
|
New words:
acute, advance, advanced, announced, BCA, bone, candidate, clinical, commercializing, contemplated, customary, DB, decrease, demonstrate, detail, develop, disease, DRE, Drug, efficacy, endpoint, ExoFlo, expedite, Extension, extracellular, FDA, Food, governmental, half, hereinafter, hospitalized, lead, letter, License, LOI, medical, medicine, mesenchymal, minimum, mortality, parent, Phase, platform, power, product, promising, proportional, proprietary, receipt, reclassified, regenerative, respiratory, Rollover, satisfaction, statutory, stem, subsidiary, surviving, syndrome, technology, therapeutic, therapy, Topco, treating, trial, unmet, vesicle, Wyoming
Removed:
acquire, breach, commitment, conducting, exclusivity, favorable, intention, paying, satisfy, shopping
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view